Novartis has agreed to acquire Anthos Therapeutics, a Boston-based clinical-stage biopharmaceutical company, for an upfront ...

Blackstone Life Sciences has sold Anthos Therapeutics to Novartis for up to $3.1 billion. Anthos is a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...

The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in P ...

Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in ...

Flossing was associated with a 44% lower risk of cardioembolic stroke, a 22% lower risk of ischemic stroke and a 12% lower risk of atrial fibrillation, according to research presented at the American ...

The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...

Apixaban significantly reduces stroke risk in people with subclinical atrial fibrillation and prior stroke history.

In February 2024, Corewell Health introduced pulsed field ablation, a treatment procedure significantly safer than previous AFib treatments, at several of its Michigan hospitals. PFA applies a ...

IV thrombolysis given within 4.5 hours of acute pontine infarction may significantly reduce neurological deterioration vs ...